Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Zoetis Inc (ZTS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Zoetis Inc's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
202.22 +1.83    +0.91%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
203.00
+0.78
+0.39%
18:30:58 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US98978V1035 
CUSIP:  98978V103
  • Volume: 1,230,871
  • Bid/Ask: 198.00 / 203.30
  • Day's Range: 200.12 - 202.80
Zoetis Inc 202.22 +1.83 +0.91%
Bayer to sell businesses, cut jobs after Monsanto deal
Bayer to sell businesses, cut jobs after Monsanto deal By Reuters - Nov 29, 2018

By Ludwig Burger FRANKFURT (Reuters) - Bayer (DE:BAYGn), the German drugmaker that bought U.S. seed company Monsanto (NYSE:MON), announced on Thursday the sale of a number of businesses, around...

Zoetis Inc Earnings, Revenue beat in Q3
Zoetis Inc Earnings, Revenue beat in Q3 By Investing.com - Nov 01, 2018

Investing.com - Zoetis Inc (NYSE:ZTS) reported third quarter earnings that beat analyst's expectations on Thursday and revenue that topped forecasts. The firm reported earnings per share of $0.83...

Animal health firm Elanco surges 41 percent on debut
Animal health firm Elanco surges 41 percent on debut By Reuters - Sep 20, 2018 1

By Aparajita Saxena (Reuters) - Eli Lilly unit Elanco Animal Health Inc's shares jumped as much as 41 percent on their stock market debut on Thursday, adding to investor enthusiasm for the...

FDA OKs BI's NexGard for prevention of Lyme disease in dogs
FDA OKs BI's NexGard for prevention of Lyme disease in dogs By Seeking Alpha - Aug 27, 2018

The FDA approves privately held Boehringer Ingelheim's NexGard (afoxolaner), a chewable flea and tick product , for the prevention of infections that cause Lyme disease, specifically, by killing the...

Zoetis beats by $0.07, beats on revenue
Zoetis beats by $0.07, beats on revenue By Seeking Alpha - Aug 02, 2018

Zoetis (NYSE:ZTS): Q2 EPS of $0.77 beats by $0.07.Revenue of $1.42B (+11.8% Y/Y) beats by $40M.Press ReleaseNow read: This Company Makes Pharmaceuticals For Animals And It Is Set To RoarOriginal...

Healthcare investors weigh bets as election risks loom
Healthcare investors weigh bets as election risks loom By Reuters - Jun 01, 2018

By Lewis Krauskopf NEW YORK (Reuters) - If 2016 is any guide, pharmaceutical, biotech and other healthcare stocks could be in for a rough summer and fall heading into another round of U.S. elections....

Notable earnings before Wednesday’s open
Notable earnings before Wednesday’s open By Seeking Alpha - May 01, 2018

ABC, ACOR, ADP, ALE, AME, AMRN, APTV, ARCC, ASC, AVA, BDC, BG, BPMC, CAMT, CBRE, CDW, CHK, CLH, CLX, CPLA, CRTO, CVS, DBD, DIN, DNOW, EGL, EL, ENBL, ENR, EXC, FLOW, FUN, GIB, GLDD, GNRC, GRMN, HFC,...

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ZTS Comments

Write your thoughts about Zoetis Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Frankie Wilson
Frankie Wilson Nov 21, 2020 3:47PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I bought in after I was offered the stock because I owned Pfizer years ago. My perspective is different because I bought in at a discount when it was under 30 dollars a share. If it takes a dip, I'll just by more. Either way I'm still have a large ROI.
Solomon Lalani
Solomon Aug 02, 2020 1:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to offload this stock.  At least 30% decline coming
Steve Fischbach
Steve Fischbach May 08, 2020 2:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Everything about this company looks good and I've been in with them since January but their price just can't seem to rise to their potential.  Selling off my shares of this boat anchor.
Piotr Szabat
Piotr Szabat May 06, 2020 10:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very intresting Stock. Who bought this?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email